Thomas Gad : Yes. Thank you. So first of all, our current isotope, as you know is lutetium, which comes from the initial construct that the platform was developed on, which is the GD2-SADA with the linker to a lutetium-177. The platform is modular. We can attach different isotopes, and we are doing work on alpha emitters as well. I think at this point, we’re very happy to stick with lutetium also considering the supply chain of actinium and other alphas, but we are definitely doing research, and we will be looking at alpha emitters going forward as well — different alpha emitters, not necessarily actinium. And on the partnership strategy, we have communicated that our strategy is to out-license larger indications and also taking third-party targets, optimizing those at SADA constructs and then keep in-house any pediatric subs.
Operator: Our next question comes from the line of Bill Maughan with Canaccord Genuity.
William Maughan : So I have two questions. First is, looking at the current run rate, which is above the high end of guidance for the year, can you — it seems to us conservative. So can you describe a scenario in which guidance — in which full year results don’t beat guidance and then return to growth long term? And then the second question is on the SADA platform. The sense has been for the past couple of months that first patient dosed was kind of imminent. And it seems that it’s taken a little longer to get that first patient in. Can you just describe what has happened in the past couple of months that’s been different from expectations?
Thomas Gad : I don’t know, Sue, if you want to — Bill, so you’re asking — your first question was asking if we don’t reach our guidance?
William Maughan : No, if you — so at $16.4 million in 4Q, you’re already at a run rate to exceed. So I think the expectation is probably that you will exceed, but just trying to paint the picture of what hitting guidance looks like?
Thomas Gad : Yes. So I think based on the fourth quarter, our guidance are conservative, and we’ll continue to monitor quarter-on-quarter basis and come out and firm up our guidance as necessary. But we wanted to be conservative. I don’t think we can clearly say we are very conservative at this point in time. And…
Sue Smith : If I could add, Thomas, I think — yes, just I think the main constraint, if you will, in a super rare market like this is that there are currently 22 pediatric neuroblastoma trials ongoing and 13 of those are with dinutuximab or dinutuximab beta. So when you have such a small number of patients and there are so many different options, I think that’s our #1 competition, if you will. So while I think that ped oncs and parents want a different option and our humanized option is an excellent one, and we’re engaged with the right people, I think that’s just the variable that we don’t want to overstate because just the small numbers in the number of different trials ongoing is probably the biggest unknown.
William Maughan : Got it. Thank you. And on the SADA patient dosing?
Thomas Gad : Yes. So we look forward to update the market once we’ve dosed the first patient. We’ve opened four sites. It takes time to open and activate. And this is a first-in-class drug that’s never been in humans before. And I think we also been selective of what kind of first patients come into the trial. But internally, I think we are happy with the progress we’ve made and we really look forward to come out and give you some good news.
Operator: Our next question comes from the line of Tessa Romero with JPMorgan.
